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Abstract
HIV-1 is grouped phylogenetically into clades, which may impact rates of HIV-1 disease progression. Clade D infection in
particular has been shown to be more pathogenic. Here we confirm in a Nairobi-based prospective female sex worker
cohort (1985–2004) that Clade D (n = 54) is associated with a more rapid CD4 decline than clade A1 (n = 150, 20.6% vs 13.4%
decline per year, 1.53-fold increase, p = 0.015). This was independent of ‘‘protective’’ HLA and country of origin (p = 0.053),
which in turn were also independent predictors of the rate of CD4 decline (p = 0.026 and 0.005, respectively). These data
confirm that clade D is more pathogenic than clade A1. The precise reason for this difference is currently unclear, and
requires further study. This is first study to demonstrate difference in HIV-1 disease progression between clades while
controlling for protective HLA alleles.
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Introduction
HIV infection is characterized by a prolonged host-pathogen
interaction that, in the absence of antiretroviral therapy,
eventually leads to CD4 decline and AIDS. The rate of HIV
disease progression is heterogeneous and driven by many factors
[1]. A better understanding of the host, viral, and environmental
factors that contribute to this heterogeneity would improve our
understanding of HIV pathogenesis and therapeutic strategies.
HIV exhibits extreme genetic diversity, in some cases differing by
more than 30% amino acid homology in the Env protein. The
HIV-1 main group (M), which accounts for most infections
globally, has been classified into numerous clades (subtypes) and
circulating recombinant forms (CRFs), with distinct geographical
distributions [2]. In sub-Saharan Africa, where the pandemic
originated [3], most countries have multiple clades and/or CRFs
in circulation.
Several previous studies have assessed the impact of HIV
subtype on the rate of disease progression. An early study in
Kenya showed that clade C was associated with faster
progression, higher viral loads, and lower CD4 counts than
clades A1 or D [4]. Another study in Senegal demonstrated that
infection by clades other than A1 was associated with an
increased risk of disease progression during the period of follow-
up [5]. Recent studies in Kenya, Tanzania, and Uganda suggest
that clade D is associated with more rapid disease progression
than clade A, ranging from approximately 1.3 to .6 times
faster [6,7,8,9]. It is unclear what immunological or virological
mechanism(s) underlie these differences [10]. One report
suggested that clade D was associated with CXCR4-tropism
[11], which has previously been associated with faster progres-
sion to AIDS [12]. Therefore, while differences in progression
between clades have been observed previously, it remains
uncertain whether these are due to differences in viral
replication. We sought to confirm the differences in CD4
decline between clades A1 and D at different stages of HIV-1
disease progression, and explore whether these were associated
with differences in HIV viral loads in vivo.
Methods
Cohort Description
We enrolled participants from a large prospective female sex
worker cohort in Nairobi, Kenya. All participants provided
informed written consent, and Institutional Review Boards at
Kenyatta National Hospital and University of Manitoba approved
the study. HIV-1 clade was determined cross-sectionally by HIV-1
p24 proviral DNA sequencing, as described (n= 377) [13]. The
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region sequenced corresponds to HXB2 positions 1,508–2,198.
Only clade A1 and D-infected participants were included; .90%
of the cohort was infected by these clades. Class I HLA haplotypes
were determined by DNA sequencing, as previously described
[13]. HLA alleles were considered protective based on their ability
to slow disease progression consistently in prior studies; protective
alleles included HLA-B*1302, B*27, B*5101, B*5701/3, and
B*8101 [14]. Participant characteristics and details of follow-up of
those infected by clades A1 and D in the present study are shown
in Table 1. CD4 counts were measured biannually in this cohort
from 1990 onwards using Becton Dickinson Tritest reagents. The
majority of the cohort (.80%) was HIV seropositive at
enrollment. All participants were ART-naive for the period of
follow-up in this study. Viral loads are not standard of care in this
cohort and were measured, where available, using Roche bDNA
viral load assay v. 3.0.
Statistical Approach
Chi-square and Mann-Whitney tests were used to compare
participant characteristics, where appropriate. Slopes of CD4
decline were analyzed using unstructured linear mixed models
with random intercept and slope. In order to ‘‘linearize’’ rates of
decline, CD4 counts were transformed using the natural log
(lnCD4). Natural log-derived parameters are more easily inter-
preted than square or cube roots, and previous reports suggest
these measures behave similar, in terms of linearization of rates of
decline, over the ranges studied [15]. In the most basic model,
decline of lnCD4 was a dependent variable, with follow-up and the
interaction between clade and time as outcome variables. Potential
confounders were then added as additional co-variables including
protective HLA (interacting with time), and country of origin
(interacting with time).
Results
Participant Characteristics
Of the 377 participants with HIV-1 sequence data, 204 were
included (54%) in this analysis on the basis of having a CD4.350
at baseline, as has been reported elsewhere [16]. No other
exclusion criteria were used. Apart from shorter duration of
follow-up and lower CD4 count (by definition), there were no
differences between excluded individuals compared to those
included in the analysis (not shown). Clade A1 was approximately
three times more common than clade D. Baseline and follow-up
data for study participants are shown in Table 1. Although there
were no statistically significant differences, clade A1-infected
participants tended to be older (median 35 vs. 32, p = 0.32), more
likely to be Kenyan (25.5 vs. 14.8%, p= 0.13), and have at least
one protective class I HLA allele (29.1 vs. 18.9%, p= 0.20). Other
participants were from Tanzania (65.5%) and Uganda (11.8%).
Clade A1 participants tended to have longer follow-up (median
2,438 vs. 2,057 days, p = 0.159) and more CD4 measurements
(median 11 vs. 8.5, p = 0.077). Many of these are consistent with
the hypothesized longer survival time for clade A1 compared to D-
infected individuals. Since VL is not standard of care, these were
only available for a random selection of clade A1 (48.7%) and D
(35.2%) participants.
Impact of Clade and Co-variates on Slope of CD4 Decline
Because time of infection is left-censored for the majority of
the cohort, survival analyses to determine the impact of clade
on time to CD4 decline below a fixed threshold (e.g. 350) were
not feasible. Therefore we used linear mixed models with
random effects (slope and intercept) to determine the impact of
clade on CD4 decline during prospective follow-up. The natural
log of CD4 (lnCD4) was the dependent variable in all models;
this measure declines linearly and is assumed to be independent
of time of infection. In the most basic model (Table 2, Model
1), including time and the interaction between clade D and
time, clade D was associated with a more rapid CD4 decline
(p = 0.015, annual estimate = 0.061, 95% CI 0.012, 0.110).
While clade D-infected individuals experienced an annual CD4
decline of 20.6%, this decline was 13.4% for clade A1,
translating to a 1.53-fold more rapid CD4 decline for clade D
than A1 (Figure 1). While CD4 cells declined by an average of
39.7 cells/year for clade A1, clade D infected participant CD4
counts declined by 50.6 cells/year. In an exploratory analysis
including only participants with a CD4.500 at baseline, the
impact of clade D on CD4 decline was also observed (not
shown).
Next we controlled for various potential confounders (Table 2,
Model 2). Age or duration of sex work had no impact on the
association between clade and CD4 decline. Baseline CD4 was
associated with time but also did not affect the clade association
(not shown). No associations between baseline CD4 and clade,
protective HLA, or country of origin were observed, and these
were omitted from further models (not shown). In a multivariate
model (Model 2), both protective HLA alleles and country of
origin were independently associated with rate of CD4 decline
(No protective HLA, p= 0.026, Estimate 20.054, 95% CI
20.102, 20.007; Non-Kenyan, p= 0.005, Estimate 20.070,
95% CI 20.119, 20.121), and these decreased the effect
observed for clade (p = 0.053, Estimate 0.048, 95% CI 20.001,
0.097). Lastly, we added average VL as a co-variate to
Table 1. Baseline characteristics of the study cohort.
Variable Clade A1 (n=150) Clade D (n=54) P value
Mean age, years (median, IQR) 35 (30–39) 32 (27–38) 0.32
Kenyan 25.5% 14.8% 0.13
Follow-up, days (median, IQR) 2,438 (1,309–3,824) 2,057 (972–3,230) 0.159
CD4 count at baseline (median, IQR) 576 (453–740) 516 (413–689) 0.133
No. of CD4 counts (median, IQR) 11 (6–16) 8.5 (4–15) 0.077
Protective HLA 29.1% 18.9% 0.20
% with VL data 48.7% 35.2% 0.11
Average log10 copies/ml (VL; median, IQR) 3.74 (3.02–4.48) 3.95 (3.53–4.91) 0.186
doi:10.1371/journal.pone.0049797.t001
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determine its impact on rates of CD4 decline. This was a sub-
analysis that included VL data where available (92/204
participants with baseline CD4.350). While follow-up and
country of origin remain significant in this model (p = 0.019 and
p= 0.021, respectively), clade and protective HLA were no
longer associated with rates of CD4 decline (not shown).
Discussion
These data support earlier findings that the rate of CD4 decline
among individuals infected with clade D is more rapid, by
approximately 50%, than those infected with clade A1. Despite
the consistency of this observation, the reason(s) that underlie it
remain unclear. One hypothesis is that clade D is associated with a
Figure 1. Scatter plot showing slopes of decline of natural log CD4 (lnCD4, y-axis) over time (x-axis). Dots indicate individual CD4
measures, while lines indicate mean slope of decline for participants infected by Clades A1 (blue) and clade D (green). These were analyzed using
linear mixed models (Table 2).
doi:10.1371/journal.pone.0049797.g001
Table 2. Results from linear mixed models examining factors associated with CD4 decline.
Variable Model 1 Model 2
Estimate (95% CI) P value Estimate (95% CI) P value
Follow Up 20.187 (20.230, 20.144) ,0.001 20.084 (20.156, 20.012) 0.022
Clade A1*follow-up 0.061 (0.012, 0.110) 0.015 0.048 (20.001, 0.097) 0.053
No Protective HLA* follow-up 2 2 20.054 (20.102, 20.007) 0.026
Kenyan*follow-up 2 2 0.070 (20.119, 20.021) 0.005
doi:10.1371/journal.pone.0049797.t002
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higher VL, perhaps as a result of increased replicative fitness.
Other hypotheses include that clade D viruses have a differential
effect on other factors that impact HIV-1 disease progression, such
as cellular tropism or immune activation. Resolution of these
differences could provide important data for better understanding
the heterogeneity of HIV-1 disease progression.
Our data suggest there is a slight (0.2 log10 copies/ml) increase
in VL associated with clade D that was not statistically significant.
While clade was a reasonable predictor of the slope of CD4 decline
in models that include several relevant co-variates, the addition of
VL nullified this association (while follow-up remained significant).
It is important to note a major limitation of our study is that VL
could only be included as a sub-analysis, and the time point of
infection for VL remains unknown. Therefore it does not appear
VL is a major determinant of the difference in rates of disease
progression between clades. Another possible future direction
would be to compare reservoir size between clades A1 and D by
measuring cell-associated VL.
Our study is the first to compare differences in HIV-1 disease
progression between clades while controlling for protective HLA
alleles. These data suggest that both clade and HLA can
contribute to rates of disease progression. HLA differences
between populations could be an important confounder in studies
of HIV pathogenesis. In addition, country of origin was a strong,
independent predictor of the rate of CD4 decline in all models.
The reasons for this are still not clear and suggest an impact of
other, unmeasured, confounders.
Previous studies of HIV-1 clade and disease have employed
several different approaches. While the methods to determine
clade are likely all valid, the HIV-1 region under study could be
important. In our study, clade was determined by sequencing and
phylogenetics of the p24 protein of HIV-1. Therefore, one
potential limitation is that recombinants may be missed due to
misclassification bias. On the contrary, our data suggest that clade
of p24 might be an important predictor of both VL and rates of
CD4 decline. Studies of CTL escape suggest p24 has many
conserved residues that are likely structurally important for virion
function [17,18]. Study of the p24 differences between clades
therefore might be an important avenue for future study.
In summary, these data add to mounting evidence that clade D
is more pathogenic than clade A1. Some studies suggest clade A1
is associated with increased transmission [19,20], possibly because
clade D viruses tend to be X4-tropic, and therefore do not readily
establish infection [21]. The above data suggest that any difference
in pathogenecity between clades will not necessarily increase the
frequency of that clade over time. We compare the differences in
clades including important co-variates such as protective HLA
alleles and country of origin. Potential mediators of clade-
associated differences in pathogenecity can only be resolved by
further studies, particularly those that focus on the earliest events
following HIV-1 infection.
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